Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Ocular Pain Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Ocular Pain Overview | 8 | 1 |
| Ocular Pain Therapeutics under Development by Companies | 9 | 1 |
| Ocular Pain Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Ocular Pain Products under Development by Companies | 13 | 1 |
| Ocular Pain Companies Involved in Therapeutics Development | 14 | 7 |
| D. Western Therapeutics Institute, Inc. | 14 | 1 |
| InSite Vision Incorporated | 15 | 1 |
| Kala Pharmaceuticals, Inc. | 16 | 1 |
| Ocular Therapeutix, Inc. | 17 | 1 |
| Reata Pharmaceuticals, Inc. | 18 | 1 |
| Sylentis S.A.U. | 19 | 1 |
| Valeant Pharmaceuticals International, Inc. | 20 | 1 |
| Ocular Pain Therapeutics Assessment | 21 | 10 |
| Assessment by Monotherapy Products | 21 | 1 |
| Assessment by Combination Products | 22 | 1 |
| Assessment by Target | 23 | 2 |
| Assessment by Mechanism of Action | 25 | 2 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 2 |
| Drug Profiles | 31 | 28 |
| (bromfenac sodium + dexamethasone acetate) Drug Profile | 31 | 1 |
| bromfenac sodium Drug Profile | 32 | 5 |
| dexamethasone acetate SR Drug Profile | 37 | 5 |
| Drug for Ocular Pain Drug Profile | 42 | 1 |
| ISV-705 Drug Profile | 43 | 1 |
| ketorolac tromethamine Drug Profile | 44 | 1 |
| loteprednol etabonate Drug Profile | 45 | 3 |
| loteprednol etabonate next generation Drug Profile | 48 | 1 |
| NT-71 Drug Profile | 49 | 1 |
| NT-72 Drug Profile | 50 | 1 |
| omaveloxolone Drug Profile | 51 | 3 |
| RX-10045 Drug Profile | 54 | 2 |
| Small Molecules to Block NaV1.7 Channel for Pain, Ocular Pain and Pruritus Drug Profile | 56 | 1 |
| SYL-1001 Drug Profile | 57 | 2 |
| Ocular Pain Dormant Projects | 59 | 1 |
| Ocular Pain Product Development Milestones | 60 | 9 |
| Featured News &Press Releases | 60 | 1 |
| Apr 09, 2016: Sun Pharma Receives USFDA Approval For BromSite | 60 | 1 |
| Mar 14, 2016: Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome | 60 | 1 |
| Sep 02, 2015: InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit | 61 | 1 |
| Aug 17, 2015: InSite Vision Announces FDA Acceptance of NDA Filing for BromSite | 61 | 1 |
| Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery | 62 | 1 |
| May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery | 62 | 1 |
| Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite | 63 | 1 |
| Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery | 63 | 1 |
| Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery | 64 | 1 |
| Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery | 64 | 1 |
| Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery | 65 | 1 |
| Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery | 66 | 1 |
| Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling | 67 | 1 |
| Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate | 68 | 1 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |